Dyne Therapeutics started the new year with proof-of-concept clinical data for experimental genetic medicines addressing two rare muscle diseases—one of which has no FDA-approved treatments. Now the ...
Monday, Dyne Therapeutics Inc (NASDAQ:DYN) released clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its ongoing Phase 1/2 ...
Inspect Point has partnered with Dyne Fire Protection Labs to connect sprinkler sampling and lab testing with inspection workflows.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results